Lung Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report By Sample Type, By Biomarker, By Technology, By End-use, By Clinical Application, By Product, By Region, And Segment Forecasts, 2024 - 2030

Lung Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report By Sample Type, By Biomarker, By Technology, By End-use, By Clinical Application, By Product, By Region, And Segment Forecasts, 2024 - 2030

Lung Cancer Liquid Biopsy Market Growth & Trends

The global lung cancer liquid biopsy market size is anticipated to reach USD 2.35 billion by 2030, growing at a CAGR of 13.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. Liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, enabling earlier detection of lung cancer. The diagnostics industry is moving towards precision medicine, which requires accurate and comprehensive diagnostic tools. Liquid biopsies offer a promising solution for providing information for personalized treatment plans.

Factors such as late detection and high mortality rates result in a decline in the overall survival rate. Lifestyle habits such as cigarette smoking and tobacco exposure are some of the significant risk factors, contributing to approximately 80% of the total lung cancer cases worldwide. According to the World Health Organization (WHO), in 2020, 22.3% of the world’s population consumed tobacco, which constitutes 36.7% of men and 7.8% of the total women. It also states that tobacco causes the deaths of more than 8 million people each year, including an estimated 1.3 million passive smokers.

Companies are launching newer technologies and products to screen lung cancers. For instance, Delfi Diagnostics launched its blood test to screen for lung cancer in October 2023. This increasing number of launches involving newer launches is anticipated to propel the market.

Lung Cancer Liquid Biopsy Market Report Highlights

• Based on sample type, the blood sample-based segment dominated the market in 2023. This can be attributed to the non-invasive nature, repeatability, real-time monitoring capabilities, early detection, and cost-effectiveness of this sample type.
• Based on biomarker, the circulating nucleic acids segment led the market in 2023 as it can be detected at very low concentrations in blood samples, even when cancer is at an early stage.
• Based on technology, the multi-gene-parallel analysis (NGS) segment dominated the market in 2023.
• North America dominated the market for lung cancer liquid biopsy in 2023, owing to factors such as the increasing prevalence of lung cancer, changes in lifestyles, advancements in healthcare, and availability of reimbursement policies.
• For instance, according to the American Cancer Society Journals, in 2022, approximately 1,918,030 new cancer cases were observed in the U.S., which included approximately 350 deaths each day from lung cancer, the leading cause of cancer death.

Please note The report will be delivered in 2-3 business days upon order notification.